Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04210115
Title Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Cisplatin + Fluorouracil + Pembrolizumab

Fluorouracil + Leucovorin + Oxaliplatin

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Cisplatin + Fluorouracil

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.